REG - ReNeuron Group plc - Block Listing Review & Total Voting Rights

ReNeuronAnnouncement

01/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240301:nRSA7940Ea&default-theme=true

RNS Number : 7940E  ReNeuron Group plc  01 March 2024

01 March 2024

 

ReNeuron Group plc

("ReNeuron" or the "Company")

 

Block Listing Review

and Total Voting Rights

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome
technologies, provides the following update in accordance with Schedule Six of
the AIM Rules for Companies regarding its existing block listing arrangements.

 

 Name:                                                                          ReNeuron Group plc
 Name of Scheme:                                                                ReNeuron Share Option Schemes
 Period of Return:                                                              From 1 September 2023 to 29 February 2024
 Balance of unallotted securities under scheme(s) from previous return:         8,600,000 Ordinary Shares (of 1p each)

 Plus: The amount by which the block scheme(s) has been increased since the     -
 date of the last Review (if any increase has been applied for):
 Less: Number of securities issued/allotted under scheme(s) during period       -
 Equals: Balance under scheme(s) not yet issued/allotted at end of period:      8,600,000 Ordinary Shares
 Number and class of securities originally admitted and the date of admission:  20,000 ordinary shares on 13 May 2010

 

Total Voting Rights

At 29 February 2024, the Company had 57,173,760 Ordinary Shares in issue, each
carrying one voting right.

 

As the Company holds no ordinary shares in treasury, the figure of 57,173,760
may be used by shareholders as the denominator for the calculation by which
they will determine if they are required to notify their interest in, or a
change in their interest in, the Company under the FCA's Disclosure Guidance
and Transparency Rules.

 

ENDS

 

Contacts:

 ReNeuron                                                              www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Executive Chairman                                         Via Walbrook PR
 John Hawkins, Chief Financial Officer

 Allenby Capital Limited (Nominated Adviser and Broker)                +44 (0)20 3328 5656
 James Reeve/George Payne/Dan Dearden-Williams (Corporate Finance)
 Stefano Aquilino/Kelly Gardiner

 (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)                              +44 (0)20 7933 8780 or reneuron@walbrookpr.com
                                                                       (mailto:reneuron@walbrookpr.com)
 Paul McManus / Alice Woodings      +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug
delivery platform with customisable cellular targeting capabilities for the
delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell
lines, our CustomEX™ platform can be optimised for specific tissues targets
and payloads leading to improvements in therapeutic outcome and a reduction in
off-target effects. ReNeuron offers a delivery mechanism for a variety of
payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its
conditionally immortalised induced pluripotent stem cell (iPSC) platform, the
Company can make allogeneic tissue cells of choice and has the potential to
produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRTPMMTMTTTBAI